CAR-T Mania: Could Juno Therapeutics Get Acquired Next?
Gilead Sciences (NASDAQ: GILD) recently acquired Kite Pharma (NASDAQ: KITE), but that doesn't mean an acquisition of Juno Therapeutics (NASDAQ: JUNO) is off the table. Juno Therapeutics' next-generation CAR-T, JCAR017, could wind up being safer than its competitors' offerings, and if it is, then M&A could be in its future, too.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell discuss what's at stake for Juno Therapeutics and its investors.
A full transcript follows the video.
Source: Fool.com
Gilead Sciences Inc Stock
€72.35
0.210%
With 12 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 84 € shows a slightly positive potential of 16.1% compared to the current price of 72.35 € for Gilead Sciences Inc.
